Roche Transplantation

Home | Site Map | Contact Us | Tell a Colleague | Print Page

About Roche Transplantation

Roche has been a company of firsts in transplantation, including:

CellCept® (mycophenolate mofetil), the first MPA, which is now the #1 branded immunosuppressant
Valcyte® (valganciclovir), the first and only oral ganciclovir with the bioavailability of IV
ZENAPAX® (dacluzimab), the first humanized IL-2 antibody

For over a decade, we have brought to the market innovative products that have helped improve the success of transplantation. Our focus has been on improving long-term outcome with the immunosuppressant protocols and minimizing the risk of viral infections.

We continue to look for new and innovative ways to advance transplantation care.

Experience in Immunosuppression Roche has over a decade of experience in improving long-term outcomes and enhancing the quality of life of transplant recipients.	Transplant Virology Roche has a heritage of finding new solutions to challenging transplant-related viral infections.


Roche Diagnostics With over 50 years of innovation in clinical chemistry and immunodiagnostics, Roche Diagnostics supports each phase of a healthcare program with specialized testing – from early recognition and routine screening, to diagnosis and therapy, through continuous monitoring of the disease’s status.	Roche Molecular Diagnostics At Roche Molecular Diagnostics, products are developed based on the Polymerase Chain Reaction (PCR) technology for highly innovative molecular diagnostics.


Roche Biomarkers Program The Roche Biomarkers Program encompasses a very broad scientific, technological and market focused on the discovery and validation of biomarkers in support of the therapy areas being pursued by Pharmaceuticals and Diagnostics.	Innovation Timeline A snapshot view of the development of Roche Pharmaceuticals from 1896 to the present.

Privacy Statement | Legal Statement | Intended for U.S. Physician Audiences Only